<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01414244</url>
  </required_header>
  <id_info>
    <org_study_id>11-271</org_study_id>
    <nct_id>NCT01414244</nct_id>
  </id_info>
  <brief_title>Glutamine for the Treatment of Patients With Irritable Bowel Syndrome</brief_title>
  <acronym>AT005291</acronym>
  <official_title>Randomized, Placebo-Controlled Trial of Glutamine for the Treatment of Patients With Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tulane University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tulane University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      New and effective treatments are needed for patients with post-infectious irritable bowel
      syndrome (PI-IBS). We conducted a randomized, placebo-controlled trial to assess the efficacy
      and safety of glutamine, an abundant amino acid in the body and the principal fuel for
      enterocytes, in patients who developed diarrhea-predominant irritable bowel syndrome with
      increased intestinal permeability following an enteric infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a double-blind trial, eligible adults with post-infectious IBS with increased intestinal
      permeability were randomly assigned to receive either glutamine (5 g three times daily) or
      placebo for eight weeks. The primary end point was the proportion of patients who had a
      reduction of â‰¥50 on the Irritable Bowel Severity Scoring System (IBS-SS).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 30, 2015</completion_date>
  <primary_completion_date type="Actual">December 30, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Irritable Bowel Symptom Severity Scale</measure>
    <time_frame>baseline and 8 weeks following therapy</time_frame>
    <description>The primary outcome measure will be a change in the Irritable Bowel Symptom Severity Scale (IBS-SS) from baseline to 8 weeks at the conclusion of therapy. The IBS-SS scale ranges from 0 to 500 (worst). A decrease in 50 or greater in the IBS-SS is considered a positive response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intestinal Permeability</measure>
    <time_frame>baseline and 8 weeks following therapy</time_frame>
    <description>The secondary outcome measure will be a change in intestinal permeability from baseline to 8 weeks at the conclusion of therapy. Intestinal permeability is measured by the urinary lactulose/mannitol ratio following ingestion of a solution of lactulose and mannitol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Frequency</measure>
    <time_frame>Baseline and 8 weeks following therapy</time_frame>
    <description>Baseline and 8 week at the conclusion of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Consistency</measure>
    <time_frame>Baseline and 8 weeks following therapy</time_frame>
    <description>Bristol Stool Scale The Bristol Stool Scale characterizes stool characteristics and ranges from a minimum score of 1 with depicts hard or constipated stool to a maximum score of 7 which is watery or diarrheal stools. In this trial, stool that is less than 7 is better and depicts a good outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Diarrhea-Predominant Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Glutamine supplementation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glutamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Whey protein powder</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glutamine</intervention_name>
    <description>Drug</description>
    <arm_group_label>Glutamine supplementation</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>L-Glutamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men and women age 18-72 years old who developed post-infectious diarrhea-predominant
             IBS (D-IBS)

          -  increased intestinal permeability on Lactulose/Mannitol permeability test

          -  able and willing to cooperate with the study

          -  *absence of alcohol or NSAIDs ingestion for 2 weeks prior to inclusion into study and
             throughout the study duration

        Exclusion Criteria:

          -  current participation in another research protocol or unable to give informed consent

          -  women with a positive urine pregnancy test or breastfeeding

          -  history of inflammatory bowel disease, lactose intolerance, and/or celiac sprue

          -  + hydrogen breath test for bacterial overgrowth

          -  + antiendomysial antibody titer

          -  use of nonsteroidal antinflammatory drug(NSAIDs) 2 weeks before or during the study

          -  known allergy to glutamine

          -  abdominal surgery except for removal of gallbladder, uterus, or appendix

          -  Abnormal blood urea nitrogen(BUN) and/or creatinine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>QiQi Zhou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tulane University School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2011</study_first_submitted>
  <study_first_submitted_qc>August 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2011</study_first_posted>
  <results_first_submitted>April 10, 2017</results_first_submitted>
  <results_first_submitted_qc>August 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 9, 2017</results_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tulane University</investigator_affiliation>
    <investigator_full_name>Nicholas Verne</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>Glutamine</keyword>
  <keyword>Intestinal Permeability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Some data will be available through publications, however further plans to make all IPD available is unknown.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Glutamine</title>
          <description>Oral Glutamine Powder</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Oral Whey Protein Powder</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glutamine</title>
          <description>Oral Glutamine Powder</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Oral Whey Protein Powder</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="106"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.4" spread="9.5"/>
                    <measurement group_id="B2" value="30.9" spread="7.1"/>
                    <measurement group_id="B3" value="31.7" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Irritable Bowel Symptom Severity Scale</title>
        <description>The primary outcome measure will be a change in the Irritable Bowel Symptom Severity Scale (IBS-SS) from baseline to 8 weeks at the conclusion of therapy. The IBS-SS scale ranges from 0 to 500 (worst). A decrease in 50 or greater in the IBS-SS is considered a positive response.</description>
        <time_frame>baseline and 8 weeks following therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glutamine</title>
            <description>Oral Glutamine Powder</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral Whey Protein Powder</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Irritable Bowel Symptom Severity Scale</title>
          <description>The primary outcome measure will be a change in the Irritable Bowel Symptom Severity Scale (IBS-SS) from baseline to 8 weeks at the conclusion of therapy. The IBS-SS scale ranges from 0 to 500 (worst). A decrease in 50 or greater in the IBS-SS is considered a positive response.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181" spread="48"/>
                    <measurement group_id="O2" value="301" spread="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intestinal Permeability</title>
        <description>The secondary outcome measure will be a change in intestinal permeability from baseline to 8 weeks at the conclusion of therapy. Intestinal permeability is measured by the urinary lactulose/mannitol ratio following ingestion of a solution of lactulose and mannitol.</description>
        <time_frame>baseline and 8 weeks following therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glutamine</title>
            <description>Oral Glutamine Powder</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral Whey Protein Powder</description>
          </group>
        </group_list>
        <measure>
          <title>Intestinal Permeability</title>
          <description>The secondary outcome measure will be a change in intestinal permeability from baseline to 8 weeks at the conclusion of therapy. Intestinal permeability is measured by the urinary lactulose/mannitol ratio following ingestion of a solution of lactulose and mannitol.</description>
          <units>lactulose/mannitol (L/M)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.01"/>
                    <measurement group_id="O2" value="0.10" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stool Frequency</title>
        <description>Baseline and 8 week at the conclusion of therapy</description>
        <time_frame>Baseline and 8 weeks following therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glutamine</title>
            <description>Oral Glutamine Powder</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral Whey Protein Powder</description>
          </group>
        </group_list>
        <measure>
          <title>Stool Frequency</title>
          <description>Baseline and 8 week at the conclusion of therapy</description>
          <units>stools per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="0.9"/>
                    <measurement group_id="O2" value="5.3" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stool Consistency</title>
        <description>Bristol Stool Scale The Bristol Stool Scale characterizes stool characteristics and ranges from a minimum score of 1 with depicts hard or constipated stool to a maximum score of 7 which is watery or diarrheal stools. In this trial, stool that is less than 7 is better and depicts a good outcome.</description>
        <time_frame>Baseline and 8 weeks following therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glutamine</title>
            <description>Oral Glutamine Powder</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral Whey Protein Powder</description>
          </group>
        </group_list>
        <measure>
          <title>Stool Consistency</title>
          <description>Bristol Stool Scale The Bristol Stool Scale characterizes stool characteristics and ranges from a minimum score of 1 with depicts hard or constipated stool to a maximum score of 7 which is watery or diarrheal stools. In this trial, stool that is less than 7 is better and depicts a good outcome.</description>
          <units>units on a scale (1-7)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="1.2"/>
                    <measurement group_id="O2" value="6.6" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Glutamine</title>
          <description>Oral Glutamine Powder</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Oral Whey Protein Powder</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>QiQi Zhou</name_or_title>
      <organization>Tulane University</organization>
      <phone>988-7800</phone>
      <email>qiqi06@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

